Background: The appropriate surgical treatment of effort thrombosis in young patients with venous thoracic outlet syndrome (TOS) is controversial. The major approaches include supraclavicular, infraclavicular, paraclavicular, and transaxillary first rib resection. We present the successful paraclavicular surgical management for the relatively rare observation of recurrent venous TOS with effort thrombosis 5 years after transaxillary rib resection.
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Case presentation: This is a 23-year-old woman and professional athlete who had a previous left first rib transaxillary resection in 2012 at an outside institution for venous TOS of the subclavian vein and developed recurrence of massive left upper extremity swelling and pain. She initially underwent balloon angioplasty, with suggestion of hypercoagulability as the cause for recurrence. Subsequent imaging 5 years later at our institution showed subclavian vein thrombosis, and this was confirmed with dynamic venography. A paraclavicular thoracic outlet decompression with complete first rib resection to the sternum and cervical spine was performed, followed by thrombolysis of the subclavian vein and balloon angioplasty. Success was confirmed with a patent subclavian vein on intraoperative dynamic venography and complete elimination of symptoms postoperatively.
Conclusions: This case demonstrates that recurrence of symptoms after transaxillary first rib resection is potentially due to residual first rib compression at the costoclavicular junction. Additional surgical decompression with complete first rib resection may be necessary to prevent recurrent venous compression and thrombosis. Objective: Thoracic endovascular aortic repair (TEVAR) has expanded access to thoracic aortic aneurysm (TAA) repair, particularly for elderly and frail patients. However, there are limited data on this higher risk population to inform appropriate selection of patients. Our objective was to develop and to validate a frailty-based, procedure-specific risk score for patients undergoing TEVAR for elective TAA.
Methods: Patients undergoing nonemergent TEVAR for TAA during 2005 to 2016 in the National Surgical Quality Improvement Program database were randomized to derivation or validation cohorts. The primary outcome was 30-day major adverse events (MAEs), including mortality and major complications. Using the derivation cohort, variables associated with MAEs were identified by univariable analyses. Those with P < .05 were included in multivariable logistic regression analysis. Independent procedure-specific and frailty-related risk factors for MAEs were used to develop a pragmatic score to assess risk for TEVAR.
Results: Overall, 1920 patients were included (960 derivation, 960 validation); 16% of derivation patients had MAEs (15% major complications, 4% mortality), which were primarily associated with markers of frailty and TEVAR extent (Table) . Independent risk factors for MAEs were chronic pulmonary disease (odds ratio [OR], 1.8; 95% confidence interval [CI], 1.3-2.6), functional dependence (OR, 2.9; 95% CI, 1.7-5.2), and zone 2 involvement (OR, 1.7; 95% CI, 1.2-2.4). Assigning each variable 1 point, a total risk score of 0 to 3 was generated with progressive rates of MAEs (Fig) , enabling classification as low risk (0 points; 38% of patients; mortality <5%; MAEs <15%), intermediate risk (1 point; 45% of patients; mortality <10%; MAEs <20%), or high risk ($2 points; 17% of patients; mortality >10%; MAEs >20%). Validation patients had similar characteristics and calculated risk profile.
Conclusions: Markers of frailty and procedure extent strongly predict MAEs after TEVAR for TAA and can improve selection of patients by enabling patient-and procedure-specific risk stratification. Whereas TEVAR is safe in low-risk patients, intermediate-risk patients warrant careful discussion of the risks and benefits of aortic intervention; under certain circumstances, high-risk patients may not benefit. Further study is required to define the association between frailty and long-term outcomes. 
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